找回密码
 To register

QQ登录

只需一步,快速开始

扫一扫,访问微社区

Titlebook: Ovarian Cancers; Advances through Int Eric Pujade-Lauraine,Isabelle Ray-Coquard,Fabrice Book 2017 Springer International Publishing Switze

[复制链接]
查看: 15534|回复: 56
发表于 2025-3-21 19:43:47 | 显示全部楼层 |阅读模式
书目名称Ovarian Cancers
副标题Advances through Int
编辑Eric Pujade-Lauraine,Isabelle Ray-Coquard,Fabrice
视频video
概述Presents the unique expertise of international investigating groups in ovarian cancers.An up-to-date review of current management of ovarian cancers with a large focus on rare ovarian cancers.Advances
图书封面Titlebook: Ovarian Cancers; Advances through Int Eric Pujade-Lauraine,Isabelle Ray-Coquard,Fabrice  Book 2017 Springer International Publishing Switze
描述.This book provides an overview of the latestdevelopments in the concepts and management of ovarian cancer. The new datapresented throughout opens the way to radically different therapeuticapproaches. Surgery remains the core of ovarian cancer treatment, but itsultimate goal and the standard surgical procedure have evolved, giving rise tothe question of how to label expert centers for debulking surgery. Neo-adjuvantchemotherapy is becoming more popular and is also a new field for testing noveldrug combinations..Over recent years, ovarian cancer managementhas embraced molecular biology. It is now more correct to talk about cancers ofthe ovary rather than ovarian cancer, since it is not a unique disease butseveral entities with different molecular drivers. The significant advances indrugs targeting the microenvironment or the tumor cell DNA repair mechanismsare presented in detail together with exciting future perspectives..All these advances would not have been possiblewithout collaborative groups such as the GINECO group in France and theirintegration in wider clinical research networks at the European (ENGOT) andinternational (GCIG) level..
出版日期Book 2017
关键词Cancer therapeutics; Clinical research; Onco-fertility; Ovarian rare cancers; Quality of Life; surgical o
版次1
doihttps://doi.org/10.1007/978-3-319-32110-3
isbn_softcover978-3-319-81199-4
isbn_ebook978-3-319-32110-3
copyrightSpringer International Publishing Switzerland 2017
The information of publication is updating

书目名称Ovarian Cancers影响因子(影响力)




书目名称Ovarian Cancers影响因子(影响力)学科排名




书目名称Ovarian Cancers网络公开度




书目名称Ovarian Cancers网络公开度学科排名




书目名称Ovarian Cancers被引频次




书目名称Ovarian Cancers被引频次学科排名




书目名称Ovarian Cancers年度引用




书目名称Ovarian Cancers年度引用学科排名




书目名称Ovarian Cancers读者反馈




书目名称Ovarian Cancers读者反馈学科排名




单选投票, 共有 1 人参与投票
 

0票 0.00%

Perfect with Aesthetics

 

0票 0.00%

Better Implies Difficulty

 

0票 0.00%

Good and Satisfactory

 

1票 100.00%

Adverse Performance

 

0票 0.00%

Disdainful Garbage

您所在的用户组没有投票权限
发表于 2025-3-21 22:49:06 | 显示全部楼层
http://image.papertrans.cn/o/image/705205.jpg
发表于 2025-3-22 01:04:42 | 显示全部楼层
https://doi.org/10.1007/978-3-319-32110-3Cancer therapeutics; Clinical research; Onco-fertility; Ovarian rare cancers; Quality of Life; surgical o
发表于 2025-3-22 07:39:29 | 显示全部楼层
Clear Cell CarcinomaClear cell carcinoma (CCC) is a unique entity of adenocarcinoma of the ovary. In this chapter, we discuss the clinicopathological and molecular biological characteristics of CCC. The results of clinical trials conducted in the past strongly imply the chemoresistance of CCC, and clinical trials using targeted agents are ongoing.
发表于 2025-3-22 09:57:14 | 显示全部楼层
发表于 2025-3-22 15:50:32 | 显示全部楼层
发表于 2025-3-22 19:39:59 | 显示全部楼层
发表于 2025-3-22 22:20:55 | 显示全部楼层
Ovarian Cancer and HIPEC: In the Era of Evidence Based Medicineatment of advanced ovarian cancer..HIPEC is an innovative treatment. Before using it outside clinical trials in the case of initial treatment of advanced ovarian cancer, or in the case of the first relapse, results of large multi-institutionnal randomised trials built to assess impact on survival, are required.
发表于 2025-3-23 04:18:17 | 显示全部楼层
发表于 2025-3-23 08:05:13 | 显示全部楼层
How to Evaluate Tumor Burden Before Therapeutic Decision serum markers, and disease extension. Here we describe more advanced techniques to assess pre-operative tumor burden, ongoing clinical trials and integrated clinical models to individualize therapeutic decision.
 关于派博传思  派博传思旗下网站  友情链接
派博传思介绍 公司地理位置 论文服务流程 影响因子官网 SITEMAP 大讲堂 北京大学 Oxford Uni. Harvard Uni.
发展历史沿革 期刊点评 投稿经验总结 SCIENCEGARD IMPACTFACTOR 派博系数 清华大学 Yale Uni. Stanford Uni.
|Archiver|手机版|小黑屋| 派博传思国际 ( 京公网安备110108008328) GMT+8, 2025-6-7 23:04
Copyright © 2001-2015 派博传思   京公网安备110108008328 版权所有 All rights reserved
快速回复 返回顶部 返回列表